Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 13:14:1071.
doi: 10.3332/ecancer.2020.1071. eCollection 2020.

Repurposing of drugs for triple negative breast cancer: an overview

Andrea Spini  1   2 , Sandra Donnini  3 , Pan Pantziarka  4 , Sergio Crispino  4   5 , Marina Ziche  1
Affiliations
Review

Repurposing of drugs for triple negative breast cancer: an overview

Andrea Spini et al. Ecancermedicalscience. .

Abstract

Breast cancer (BC) is the most frequent cancer among women in the world and it remains a leading cause of cancer death in women globally. Among BCs, triple negative breast cancer (TNBC) is the most aggressive, and for its histochemical and molecular characteristics is also the one whose therapeutic opportunities are most limited. The REpurposing Drugs in Oncology (ReDO) project investigates the potential use of off patent non-cancer drugs as sources of new cancer therapies. Repurposing of old non-cancer drugs, clinically approved, off patent and with known targets into oncological indications, offers potentially cheaper effective and safe drugs. In line with this project, this article describes a comprehensive overview of preclinical or clinical evidence of drugs included in the ReDO database and/or PubMed for repurposing as anticancer drugs into TNBC therapeutic treatments.

Keywords: clinical studies; non-cancer drug; preclinical studies; repositioning; triple negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest

Figures

Figure 1.
Figure 1.. Type of studies per drug. This shows the number of clinical trials (only phase 1 and 2 studies were found) and observational studies conducted per drug/pharmacological classes.
See this image and copyright information in PMC

References

    1. Perou CM. Molecular stratification of ripple-negative breast cancers. Oncologist. 2010;15(S5):39–48. doi: 10.1634/theoncologist.2010-S5-39. - DOI - PubMed
    1. Brouckaert O, Wildiers H, Floris G, et al. Update on triple-negative breast cancer: prognosis and management strategies. Int J Women’s Health. 2012;4:511–520. - PMC - PubMed
    1. Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract. 2011;2011:696208. - PMC - PubMed
    1. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–4434. doi: 10.1158/1078-0432.CCR-06-3045. - DOI - PubMed
    1. Spini A, Roberto G, Gini R, et al. Evidence of β-blockers drug repurposing for the treatment of triple negative breast cancer: a systematic review. Neoplasma. 2019;66(6):963–970. doi: 10.4149/neo_2019_190110N34. - DOI - PubMed

LinkOut - more resources